Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 251 to 275 of 1145 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
895 increased cleft upper lip (MP:0005170) 2042: Increase, Orofacial clefting
894 increased Cleft palate (HP:0000175) 2042: Increase, Orofacial clefting
893 decreased abnormal palatal shelf fusion at midline (MP:0009887) secondary palate (UBERON:0001716) None
892 decreased palatal shelves fail to meet at midline (MP:0009888) primary palate (UBERON:0005620) None
891 decreased secondary palatal shelf (UBERON:0005619) None
890 decreased gene expression (GO:0010467) zinc finger protein GLI2 (PR:000008027) 2040: Decrease, GLI1/2 target gene expression
889 decreased gene expression (GO:0010467) zinc finger protein GLI1 (PR:000008026) 2040: Decrease, GLI1/2 target gene expression
888 decreased gene expression (GO:0010467)
887 increased gene expression (GO:0010467)
886 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI2 (PR:000008027) 2028: Decrease, GLI1/2 translocation to nucleus
885 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI1 (PR:000008026) 2028: Decrease, GLI1/2 translocation to nucleus
884 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI1 (human) (PR:P08151) None
883 decreased regulation of receptor activity (GO:0010469) smoothened (PR:000015288) 2027: Antagonism, Smoothened receptor
882 decreased smoothened (PR:000015288) None
881 decreased receptor antagonist activity (GO:0048019) smoothened homolog (human) (PR:Q99835) None
880 occurrence cellular response to exogenous dsRNA (GO:0071360) RNA viral genome (GO:0019022) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
879 decreased type I interferon signaling pathway (GO:0060337) interferon beta (PR:000024939) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
878 decreased type I interferon signaling pathway (GO:0060337) interferon alpha (PR:000024938) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
877 occurrence endocytosis involved in viral entry into host cell (GO:0075509) cathepsin L1 (human) (PR:P07711) 1738: SARS-CoV-2 cell entry
876 occurrence membrane fusion (GO:0061025) transmembrane protease serine 2 (PR:000016456) 1738: SARS-CoV-2 cell entry
875 occurrence membrane fusion (GO:0061025) host cell membrane (GO:0033644) None
874 occurrence protease binding (GO:0002020) transmembrane protease serine 2 (PR:000016456) None
873 occurrence endocytosis involved in viral entry into host cell (GO:0075509) host cell membrane (GO:0033644) None
872 occurrence receptor binding (GO:0005102) angiotensin-converting enzyme 2 (PR:000003622) 1739: Binding to ACE2
871 increased Malignant mesothelioma (HP:0100001) mesothelioma (MESH:D008654) 1090: Increased, mesotheliomas